Bird & Bird advises PKN Orlen on establishing a joint venture with Synthos Green Energy

Bird & Bird has advised PKN Orlen S.A. on a joint venture with Synthos Green Energy S.A. established to prepare and commercialise the technology of small and medium nuclear reactors in Poland, in particular the BWRX-300 reactors of GE Hitachi Nuclear Energy.

The joint venture will contribute to Poland achieving carbon neutral emission by 2050 and at the same time to increasing energy security and facilitating economic growth in Poland thanks to local supply chains. Our assistance included preparing and negotiating transaction documents, including shareholders agreements, preparing a merger notification, and representing PKN Orlen S.A. in proceedings before the Office of Competition and Consumer Protection.

The project was managed by Rafał Dziedzic, partner and head of Bird & Bird’s Corporate and M&A practice, and assisted by Artur Stosio, Counsel and Mariya Borsuk, Associate.

Marcin Alberski, Senior Associate and Stanisław Szymanek, Associate in the Bird & Bird Competition and Consumer Protection team were responsible for the merger control filings and represented PKN Orlen S.A. in proceedings before the Office of Competition and Consumer Protection.

"We are delighted to have been able to advise PKN Orlen on this major project which when completed will truly increase the power security and independence of Poland and the entire region. This is yet another such large transaction which we have carried out with the ORLEN Group", says Rafał Dziedzic.


News & Deals

More News & Deals

Deal

Bird & Bird advises World of Women on its transaction to join the Tezos ecosystem

Jul 23 2024

Read More

Deal

Bird & Bird advised EIFFEL GAZ VERT on an investment in the biogas sector

Jul 23 2024

Read More

News

Bird & Bird grows its Finance practice in Italy with the arrival of two new partners

Jul 19 2024

Read More

Deal

Bird & Bird has advised Dopay on its $13.5 million Series A Extension round

Jul 19 2024

Read More

News

Bird & Bird advises iX Biopharma on rights issue

Jul 15 2024

Read More

Deal

Bird & Bird advises HSS on SciRhom’s EUR 63 million Series A financing round

Jul 11 2024

Read More